



Riccione 21-23 Ottobre 2021



13° CONGRESSO NAZIONALE
Italian Conference on AIDS and Antiviral Research

re-search for re-start together

Elenco Oral Posters

Orario	ID	Title	Presenting Author
22/10/2021 13.15 - 14.15 Antiretroviral Therapy I			
13.15 - 13.20	223	OP 1 Real-life Experience with Dolutegravir-Based Two-Drug Regimens	Rachele Pincino, Genova
13.22 - 13.27	28	OP 2 Comparison of efficacy and tolerability of Dolutegravir / Rilpivirine or Dolutegravir / Lamivudine in experienced HIV-1 positive patients switched from a three-drug regimen based on Non-Nucleoside Reverse Transcriptase Inhibitors in a single center in Italy	Filippo Lagi, Firenze
13.29 - 13.34	123	OP 3 Efficacy and safety of switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in virologically-suppressed HIV patients (EBONY Study)	Stefania Cicalini, Roma
13.36 - 13.41	14	OP 4 Efficacy and tolerability of a switch to bictegravir/emtricitabine/tenofovir alafenamide in virally suppressed PLWH	Diana Canetti, Milano
13.43 - 13.48	73	OP 5 Efficacy, safety and feasibility of a rapid antiretroviral therapy starting B/F/TAF in advanced hiv disease (Rainbow study)	Marta Camici, Roma
13.50 - 13.55	26	OP 6 Effectiveness, safety and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in people living with HIV (PLWH) in routine clinical practice: 6-month results of the Italian BICSTaR cohort	Antonella d'Arminio Monforte, Milano
22/10/2021 13.15 - 14.15 Comorbidities / Miscellaneous			
13.15 - 13.20	212	OP 7 MARAND-X: clinical trial on the use of less neurotoxic antiretrovirals in HAND	Alessandro Lazzaro, Roma
13.22 - 13.27	17	OP 8 Management of diabetes mellitus in people living with HIV and diabetes: a single-center experience	Chiara Resnati, Milano
13.29 - 13.34	279	OP 9 The interplay between resilience and health related quality of Life in PLWH during the COVID era: a comparison of a geriatric cohort with a cohort of PLWH younger than 65 years	Giovanni Guaraldi, Modena
13.36 - 13.41	24	OP 10 Efficacy and Tolerability of Doravirine + Raltegravir combination regimen as therapy of switch in ART experienced PLWHIV: the DOR-INI experience	Mariacristina Poliseno, Bari
13.43 - 13.48	193	OP 11 Trends of polypharmacy and 2DR antiretroviral use: a 15-year observational matched-cohort study	Samuele Cantergiani, Modena
13.50 - 13.55	148	OP 12 Rapid, drug-resistance-driven, start of antiretroviral therapy: an open-label, prospective, proof-of-concept, clinical study (TWODAY Study)	Nicola Gianotti, Milano
22/10/2021 13.15 - 14.15 HIV & Covid I			
13.15 - 13.20	240	OP 13 UV irradiation and SARS-CoV-2: a focus on UVA/UVB/UVC -inactivation on viral replication	Sergio Strizzi, Milano
13.22 - 13.27	257	OP 14 Determinants and characteristics of progressor and non progressor SARS COV-2 infected patients	Paola Zuccalà, Latina
13.29 - 13.34	167	OP 15 Metabolic associated fatty liver disease is highly prevalent in the post-acute COVID syndrome	Jovana Milic, Modena
13.36 - 13.41	272	OP 16 Assessment of well-being, resilience and intrinsic capacity in patients with post-acute COVID-19 syndrome	Tommaso Marchio, Modena
13.43 - 13.48	13	OP 17 Achieving virological control in pan-resistant HIV-1 infection	Diana Canetti, Milano
13.50 - 13.55	276	OP 18 Resilience and frailty in people living with HIV during the COVID era: two complementary constructs associated with health-related quality of life	Giovanni Guaraldi, Modena



Riccione 21-23 Ottobre 2021



13° CONGRESSO NAZIONALE
Italian Conference on AIDS and Antiviral Research

re-search for re-start together

Elenco Oral Posters

Orario	ID	Title	Presenting Author
22/10/2021 13.15 - 14.15 Coinfections and Hepatitis			
13.15 - 13.20	53	OP 19 Impact of polypharmacy and aging on the risk of multiple drug-drug interactions (DDIs) in HCV patients treated with pangenotypic direct-acting antivirals (pDAA)	Nicola Coppola, Napoli
13.22 - 13.27	162	OP 20 HBeAg levels vary across the different phases of HBV infection, and can be predictive of therapeutic outcome in the setting of immunosuppression-driven HBV reactivation	Lorenzo Piermatteo, Roma
13.29 - 13.34	181	OP 21 HCV knowledge and awareness among injecting drug users in the direct acting antivirals era	Antonio Boschini, Rimini
13.36 - 13.41	6	OP 22 A pilot intervention for HCV elimination among MSM in Rome: an update on more than 1200 screened individuals	Pierluca Piselli, Roma
13.43 - 13.48	253	OP 23 Humoral response to mRNA SARS-CoV-2 vaccine in cirrhotic patients without prior exposure to the virus	Chiara Sorace, Roma
13.50 - 13.55	186	OP 24 Syphilis reinfection in people living with HIV (PLWH): a monocentric retrospective study	Giorgio Tiecco, Brescia
22/10/2021 13.15 - 14.15 Immunopathogenesis I			
13.15 - 13.20	11	OP 25 Decreased neutralization of the B.1.525 (Nigerian) SARS-CoV-2 variant by sera of previously infected and uninfected vaccinated individuals	Ilaria Vicenti, Siena
13.22 - 13.27	71	OP 26 Severity of COVID-19 patients predicted by serum sphingolipids signature	Enrica Torretta, Milano
13.29 - 13.34	149	OP 27 Expansion of myeloid derived suppressor cells contribute to platelet activation by L-Arginine deprivation during SARS-CoV-2 infection	Alessandra Sacchi, Roma
13.36 - 13.41	215	OP 28 Cysteamine is an approved drug with antiviral and immunomodulatory properties promising for COVID-19 treatment	Tonino Alonzi, Roma
13.43 - 13.48	226	OP 29 High CD169 monocyte/lymphocyte ratio reflects the immunophenotyping disruption and predicts oxygen need in COVID-19 patients	Marialaura Fanelli, Roma
13.50 - 13.55	207	OP 30 Effect of SARS-CoV-2 sequences on immune response in A549-ACE2 lung cells	Gioia Cappelletti, Milano
22/10/2021 13.15 - 14.15 Epidemiology / Social Sciences I			
13.15 - 13.20	42	OP 31 SARS-CoV-2 evolutionary dynamics in the first phase of the epidemic in Italy	Alessia Lai, Milano
13.22 - 13.27	278	OP 32 Characterization of SARS-CoV-2 variants circulating in Central Italy by deep-sequencing of full-length S gene	Maria Concetta Bellocchi, Roma
13.29 - 13.34	114	OP 33 Impact of COVID pandemic and anti-SARS-CoV-2 immunization on vaccination against sexually transmitted infections	Roberto Rossotti, Milano
13.36 - 13.41	206	OP 34 Influenza vaccine: knowledge and beliefs among adherent PLWH during the first seasonal campaign of the COVID-19 era	Samuele Storti, Brescia
13.43 - 13.48	211	OP 35 Results of a SARS-CoV-2 worker screening in the Marche Nord companies to prevent virus infection in the workplace	Anna Casabianca, Urbino
13.50 - 13.55	196	OP 36 A mixed method of follow-up with total patient care provided continuum with saving of hospital checks during the COVID-19 pandemic	Paolo Fusco, Catanzaro



Riccione 21-23 Ottobre 2021



13° CONGRESSO NAZIONALE
Italian Conference on AIDS and Antiviral Research

re-search for re-start together

Elenco Oral Posters

Orario	ID	Title	Presenting Author
22/10/2021 13.15 - 14.15 Epidemiology / Social Sciences II			
13.15 - 13.20	141	OP 37 HIV-related internalized stigma and patient health engagement (PHE) model in an Italian cohort of people living with HIV	Valentina Massaroni, Roma
13.22 - 13.27	1	OP 38 Talking about stigma and Hiv prevention, the artists' contribution	Giacomo Dessì, Cagliari
13.29 - 13.34	86	OP 39 A visual scale to evaluate the quality of life in PLWHA. Fourth-90, utopia or reality?	Francesco Paciosi, Perugia
13.36 - 13.41	121	OP 40 Health-related quality of life (HRQoL) from HIV patients' perspective: comparison of patients-reported outcome (PRO) measures among people living with HIV (PLWH) and other chronic clinical conditions	Cristina Seguiti, Roma
13.43 - 13.48	40	OP 41 Using technology to support vulnerable PLWHIV at the time of coronavirus	Stefano Patrucco, Torino
13.50 - 13.55	74	OP 42 Impact of SARS-CoV-2 pandemic on quality of life in people with HIV	Marco Fois, Sassari
23/10/2021 13.15 - 14.15 Antiretroviral Therapy II			
13.15 - 13.20	3	OP 43 Changes in serum inflammatory and immune activation markers associated with lamivudine/dolutegravir and tenofovir alafenamide/emtricitabine/bictegravir as initial antiretroviral treatment	Leonardo Calza, Bologna
13.22 - 13.27	21	OP 44 Cardiovascular risk and lipid profile after switching to TAF/FTC/RPV or TAF/FTC/EVG/cobi in people living with HIV and controlled plasma viremia	Stefano Rusconi, Legnano MI
13.29 - 13.34	68	OP 45 Who could be eligible for long-acting antiretroviral treatment? A snapchat from Antiviral Response Cohort Analysis (ARCA) Italian cohort	Andrea De Vito, Sassari
13.36 - 13.41	47	OP 46 HIV-DNA decay in ART-naïve patients starting dolutegravir plus lamivudine vs triple therapy	Francesca Lombardi, Roma
13.43 - 13.48	190	OP 47 Real-life impact of drug toxicity on dolutegravir tolerability: clinical practice data from a multicenter Italian cohort	Gianmaria Baldin, Olbia
13.50 - 13.55	89	OP 48 Prevalence and incidence of multidrug resistance in the ARCA database, 2020 update	Francesca Incardona, Roma
23/10/2021 13.15 - 14.15 HIV & Covid II			
13.15 - 13.20	261	OP 49 Real life use of the anti-SARS CoV-2 monoclonal antibodies in the early phase of infection: planning, enrollment, administration and monitoring	Cosmo Del Borgo, Latina
13.22 - 13.27	151	OP 50 Learning by doing: effects of monoclonal antibody treatment on the outcome of ambulatory patients with COVID-19	Cristiana Leanza, Roma
13.29 - 13.34	46	OP 51 Efficacy, safety and virological clearance in course of treatment with anti-SARS-CoV-2 monoclonal antibodies in patients diagnosed with mild-moderate COVID-19	Camilla Falcinella, Milano
13.36 - 13.41	25	OP 52 Ex vivo efficacy of currently licensed anti-SARS-CoV-2 monoclonal antibodies	Filippo Dragoni, Siena
13.43 - 13.48	135	OP 53 Real-life use of remdesivir-containing regimens in Coronavirus Disease -2019: a retrospective case-control study	Francesco Cogliati Dezza, Roma
13.50 - 13.55	217	OP 54 SARS-CoV-2 infection Among Persons living with HIV	Serena Rita Bruno, Foggia



Riccione 21-23 Ottobre 2021



13° CONGRESSO NAZIONALE
Italian Conference on AIDS and Antiviral Research

re-search for re-start together

Elenco Oral Posters

Orario	ID	Title	Presenting Author
23/10/2021 13.15 - 14.15 Immunopathogenesis II			
13.15 - 13.20	108 OP 55	Increased rates of indeterminate QuantiFERON-TB Gold Plus assay in severe COVID-19 patients reflect an impaired interferon-gamma secretion and correlate with the profound reduction of T-lymphocyte subsets in peripheral blood	Alessandra Imeneo, Roma
13.22 - 13.27	209 OP 56	Role of serum E-selectin as a biomarker of infection severity in Coronavirus Disease-19	Emanuele Rando, Roma
13.29 - 13.34	159 OP 57	Effects of viremia and CD4 recovery on the gut "microbiome-immunity" axis in naïve HIV-1 patients undergoing ART therapy	Giulia Nannini, Firenze
13.36 - 13.41	103 OP 58	Cytokine profile of COVID-19 patients with and without active tuberculosis	Simone Villa, Milano
13.43 - 13.48	210 OP 59	Role of Tocilizumab in down regulating the concentration of sCD163 in a cohort of SARS-COV 2 infected patients with varying severity	Anna Carraro, Roma
13.50 - 13.55	229 OP 60	Clinical and immunological characterization of SARS-CoV-2 infection in children	Marta Stracuzzi, Milano
23/10/2021 13.15 - 14.15 Immunopathogenesis III			
13.15 - 13.20	184 OP 61	Binding and neutralizing antibodies to interferon (IFN) α/β and defective IFN transcriptional profile in COVID-19 patients	Federica Frasca, Roma
13.22 - 13.27	100 OP 62	Plasma cytokine landscape reveals the importance of different molecular pathways in predicting COVID-19 severity and survival	Lara Gibellini, Modena
13.29 - 13.34	199 OP 63	Pregnant women develop a specific immunological long-lived memory against SARS-CoV-2	Claudio Fenizia, Milano
13.36 - 13.41	208 OP 64	Role of Type-I and -II interferons in SARS-CoV-2 infection: convergent effect, different mechanisms	Fiona Limanaqi, Milano
13.43 - 13.48	247 OP 65	Persistence of humoral immune response after one year from COVID-19 diagnosis: evidence from a monocentric study	Paola Saltini, Milano
13.50 - 13.55	8 OP 66	Immunogenicity and safety of two doses of BNT162b2 vaccine in very elderly subjects	Martina Beltrami, Milano
23/10/2021 13.15 - 14.15 Social Sciences / Miscellaneous			
13.15 - 13.20	173 OP 67	Patient outreach strategy to enhance retention to care of HIV-positive adolescent and youths: experience from HIV high burden setting	Francesco Di Gennaro, Bari
13.22 - 13.27	98 OP 68	Knowledge of HIV and STIs: which are the most vulnerable populations? Results from a web-based survey in Italy	Agnese Colpani, Sassari
13.29 - 13.34	102 OP 69	HIV and Adolescents. Evaluation of an HIV and STI prevention project for high school students	Donatello Zagato, Milano
13.36 - 13.41	147 OP 70	SARS-CoV-2 variants surveillance highlights local emergence of different genotypes	Claudia Veneziano, Catanzaro
13.43 - 13.48	252 OP 71	Access to HIV testing before and after SARS-CoV-2 pandemic in Milan: comparison between a health-care setting and a community setting	Lorenzo Biasioli, Milano
13.50 - 13.55	49 OP 72	Characterization of PLWH with low-level viremia: results from the Italian ARCA cohort	Martina Ranzenigo, Milano



Riccione 21-23 Ottobre 2021



13° CONGRESSO NAZIONALE
Italian Conference on AIDS and Antiviral Research

re-search for re-start together

Elenco Oral Posters

Orario	ID	Title	Presenting Author
23/10/2021 13.15 - 14.15 Epidemiology / Social Sciences III			
13.15 - 13.20	176 OP 73	Pre-Exposure Prophylaxis (PrEP) through the SARS-CoV-2 pandemic period: the experience of the dedicated service of Tuscany Region in S. M. Annunziata Hospital, Florence	Elena Salomoni, Firenze
13.22 - 13.27	155 OP 74	PreP experience at Milano Checkpoint: promoting health and well-being through the integration of complementary skills	Alessandra Bianchi, Milano
13.29 - 13.34	84 OP 75	Rapid tests in the pandemic: the "continuum of care" of Villa Maraini during the Covid-19 emergency	Tania Di Giovanni, Roma
13.36 - 13.41	55 OP 76	Covid-19 in HIV/AIDS out-of-hospital facilities in Lombardy	Laura Amelia Rancilio, Milano
13.43 - 13.48	258 OP 77	The COVID-19 pandemic impact on retention in care and viral suppression at the Infectious Diseases Unit of S. M. Annunziata Hospital, Florence: comparing 2019 and 2020 data	Cecilia Costa, Firenze
13.50 - 13.55	69 OP 78	Reaching 90-90-90 in the municipality of Kilamba Kiaxi, Luanda, Angola. The experience of PIPSA project	Teresa Baldoni, Catania
23/10/2021 13.15 - 14.15 Virology			
13.15 - 13.20	172 OP 79	Molecular evidence of HIV-1 transmission in a criminal case in Italy	Lavinia Fabeni, Roma
13.22 - 13.27	242 OP 80	Assessment of specific immunological response after administration of anti-meningococcal quadrivalent conjugate vaccine MENVEO® in a population with vertically-transmitted HIV infection	Emma Longoni, Milano
13.29 - 13.34	262 OP 81	Regulation of m6A methylation as new therapeutic option against COVID-19	Carla Zannella, Napoli
13.36 - 13.41	152 OP 82	Characterization of humoral and cellular immune response after SARS-CoV-2 mRNA vaccine in HIV-1 infected patients	Letizia Santinelli, Albano Laziale
13.43 - 13.48	233 OP 83	Safety and tolerability of the Pfizer-BioNTech BNT162b2 COVID-19 vaccine in a diverse cohort of people with HIV (PWH)	Ludovica Ferrari, Roma
13.50 - 13.55	274 OP 84	Differences in response to mRNA BNT162b2 vaccine among a cohort of Health Care Workers (HCWs): insights into the potential of a booster dose	Marina Allegrini, Milano